K071633

## 510(k) SUMMARY

## Lanx Deformity System

AUG 15 2007

Submitter Information

Name and Address of Sponsor of

the 510(k) Submission:

Lanx, LLC

390 Interlocken Crescent, Suite 890

Broomfield, CO 80021

Contact Person:

Ryan Fredricey

Date of Summary Preparation:

June 13, 2007

**Device Identification** 

Proprietary Name:

Lanx Spinal Fixation System

Common Name:

Spinal Fixation System

Classification Name and Reference:

Spinal Interlaminal Fixation Orthosis

21 CFR §888.3050

Pedicle Screw Spinal System

21 CFR §888.3070

**Predicate Device Information** 

K043484 Lanx Spinal Fixation System

### **Predicate Device Identification**

The Lanx Spinal Fixation System is a posterior attachment pedicle fixation system. The system consists of a series of polyaxial screws, rods, cross connectors and interlocking mechanisms. The components are manufactured from alloyed titanium.

### **Description of Device Modification**

This submission is intended to address a line extension to the Lanx Spinal Fixation System. The line extension includes additional pedicle screw sizes/configurations, hooks, connectors and the introduction of unalloyed titanium rods.

#### **Intended Use**

The Lanx Spinal Fixation System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine: severe spondylolisthesis

\\\DC - 071676/000630 - 1991386 v2

page lof Z

K071633

(grades 3 and 4) of the L5-S1 vertebra; degenerative spondylolisthesis with objective evidence of neurologic impairment; fracture; dislocation; scoliosis; kyphosis; spinal tumor; and failed previous fusion (pseudarthrosis).

Statement of Technological Comparison

The Lanx Deformity System has the same intended use and similar indications, principles of operation, and technological characteristics as the Lanx Spinal Fixation System. The minor differences in the line item extensions items do not raise any new questions of safety or effectiveness. Mechanical testing also demonstrated comparable mechanical properties to the predicate device.

\\DC - 071676/000630 - 1991386 v2

page Z of 2





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

Lanx, LLC
Janice M. Hogan
% Hogan and Hartson, LLP
1835 Market Street, 28<sup>th</sup> Floor
Philadelphia, PA 19102

AUG 15 2007

Re:

K071633

Trade/Device Name: Lanx Deformity System Regulation Number: 21 CFR 888.3070

Regulation Name: Pedicle screw spinal system

Regulatory Class: Class II Product Code: KWP, MNI Dated: July 19, 2007

Received: July 19, 2007

Dear Ms. Hogan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at (240) 276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at (240) 276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Mark N. Melkerson

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and

melu )

Radiological Health

Enclosure

# Indications for Use Statement

510(k) Number (if known): <u>k0716</u>	33
Device Name: Lanx Spinal Fixation System	m
Indications for Use:	
The Lanx Spinal Fixation System is intended to provide immobilization and stabilization of spinal segments in skeletally mature patients as an adjunct to fusion in the treatment of the following acute and chronic instabilities or deformities of the thoracic, lumbar, and sacral spine: severe spondylolisthesis (grades 3 and 4) of the L5-S1 vertebra; degenerative spondylolisthesis with objective evidence of neurologic impairment; fracture; dislocation; scoliosis; kyphosis; spinal tumor; and failed previous fusion (pseudarthrosis).	
Prescription Use X AND/OR (Per 21 C.F.R. 801.109)	Over-The-Counter Use (Per 21 C.F.R. 807 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE CONTINUE ON ANOTHER PAGE IF NEEDED)	
Concurrence of CDRH Office of Device Evaluation (ODE)  (Division Sign-Off)	
Division of General, Restorative,	
and Neurological Devices	

\\\DC - 071676/000630 - 1991386 v2